Independent Non-Executive Director
Independent Non-Executive Director
Mr. Chen Chunguo (“Mr. Chen”), aged 45, is an executive Director and the CEO. He is also a member of each of the Nomination Committee and Remuneration committee. Mr. Chen joined the Company in October 2016 as the president and re-designated as the CEO in February 2017. Mr. Chen has 20 years of relevant experience and has accumulated abundant experience in investment and M&Aas well as corporation management. He also serves as a director of some subsidiaries of the Company. He graduated from Dongbei University of Finance and Economics and obtained a master’s degree. From 1996 to 2012, Mr. Chen served as the president of 大連實德集團 (Dalian Shide Group Co., Ltd. #) (“Dalian Shide”) who was responsible for the overall management of this 3000-employee group. Under his management, he established 8 production bases across the country for new construction materials, all of which were put into operation successfully, and developed over 100 distribution channels, making “Shide Profiles” one of the well-known brands in the People’s Republic of China (the “PRC”). During his tenure with Dalian Shide, he led the investment in and acquisition of 河北凌雲股份有限公司(Lingyun Industrial Corporation Limited# (SSE code: 600480)) and 寧夏大元股份有限公司 (Ningxia Dayuan Chemical Co., Ltd. # (SSE code:600146)), and invested in a number of financial institutions such as 大連銀行股份有限公司 (Bank of Dailian Co., Ltd. #), 太平洋保險股份有限公司 (China Pacific Insurance Co., Ltd. #), 生命人壽保險股份有限公司 (Sino Life Insurance Co., Ltd. #), 華匯人壽保險股份有限公司（Sino-Conflux Insurance Company Ltd. #）, 鐵嶺銀行股份有限 公司（Bank of Tieling Co., Ltd. #) and 景順長城基金管理有限公司 (Invesco Great Wall Fund Management Company Limited#), etc. During such period,he also formed 大連實德石化有限公司 (Dalian Shide Petrochemicals., Ltd. #), 實德集團控股有限公司（港資）（Shide Group (Hong Kong)Holdings Co., Ltd. #), 大連實德足球俱樂部 (Dalian Shide FootballClub#), 大連實德投資有限公司 (Dalian Shide Investment Co., Ltd. #)and other dozens of companies. In total, Mr. Chen managed nearly a hundred of parents and subsidiaries and a billion-dollar group during his tenure with in Dalian Shide. From 2012 to 2016, as president of 大連海潤來集團 (Hairunlai Group Co., Ltd. #), Mr. Chen has led the investment in and acquisition of 盛銀互聯網金融株式會社 (Shengyin Internet Financial Services Co., Ltd. #, based in Korea)and the investment in 百斯頓環球食品有限公司 (Beston Global Food Company Ltd#.), based in Australia, 河北唐宋互聯網大數據有限公司 (Chinatsi Big Data Inc.#) and 國金金融租賃有限公司 (Guojin Financial Leasing Co., Ltd. #), etc. In addition, Mr. Chen has integrated the group’s resources and implemented an overall transition in the group. Mr. Chen is also the chairman of 上海湧涵股權投資有限公司(Shanghai Yonghan Equity Investment Co., Ltd.#).
# for identification only
Dr. Ray Yip (“Dr. Yip”), aged 67, is a non-executive Director. Dr. Yip joined the Group in February 2017. He is also a member of each of the Audit Committee, Nomination Committee and Remuneration Committee of the Company. He is an international public health leader who has made a significant contribution to global health in the areas of nutrition, maternal and child health, HIV/AIDS and tobacco control. Dr. Yip has been working on emergency response to war and famine, long term program and policy development effort in the PRC in recent years. Dr. Yip was the founding director of the Chinese office of U.S. Centers for Disease Control and Prevention (the “CDC”) in 2013, and the China program director of the Bill and Melinda Gates Foundation(the “Foundation”) in 2017. Dr. Yip is known as a specialist for health and medical issues in the PRC.
Dr. Yip’s major contributions to the global health include: refining the international criteria for screening for malnutrition and anemia and increasing the awareness of diarrhea as a major contributor to acute malnutrition. His work in the PRC has resulted in the mainstreaming of hepatitis B vaccine for routine immunization, the adoption of hospital- based delivery as a strategy which significantly reduced maternal mortality, transformation of the national AIDS response to one targeting those high-risk groups by accepting the role of civil society and assisting in engineering the policy support for tobacco control at the top level.
Dr. Yip established the Foundation’s mission in China by assisting the government in addressing the key public health issues such as HIV and tobacco. He also transformed the Foundation’s strategy in giving it a new focus “China-for-Africa” which includes identifying successful Chinese experience and technology to assist in the development of Africa. Since 2017, Dr. Yip has served as a special advisor focusing on health and clean energy for bgC3, a think-tank headed by Bill Gates.
Dr. Yip served at the faculty of the University of California-San Francisco between 1990 and 1994 and was an adjunct professor at the Friedman School and Nutrition Science and Policy of Tufts University between 2006 and 2010. Currently, Dr. Yip is an adjunct professor at the Research Centre for Public Health of Tsinghua University.
Dr. Yip graduated from the Medical School and the School of Public Health of the University of Minnesota, and he was then certified as a pediatric haematologist-oncologist.
Mr. Chan Bing Woon, SBS, JP, (“Mr. Chan”), aged 73, is an independent non-executive Director. He is also a member of each of the Audit Committee, Nomination Committee and Remuneration Committee. Mr. Chan joined the Group in March 2014. Mr. Chan is a consultant of Yung, Yu, Yuen & Co., Solicitors and Notaries. He has over 40 years’ experience in the legal profession. Mr. Chan has been involved in numerous public duties including being Advisor of the Joint Mediation Helpline Office. He is also a fellow member of the Hong Kong Institute of Directors, a council member of the Hong Kong Society of Notaries, a general accredited mediator of Hong Kong International Arbitration Centre and the Law of Society of Hong Kong, and the chairman of the Hospital Governing Committee of Castle Peak Hospital and Siu Lam Hospital. Mr. Chan was a member of the Hospital Authority and a past chairman of the Hong Kong Mediation Council. He is currently an independent non-executive director of Kwoon Chung Bus Holdings Limited (the shares of which are listed on the Main Board of the Stock Exchange, stock code: 306).
Mr. Wong Yiu Kit Ernest (“Mr. E Wong”), aged 49, is an independent non-executive Director. He is also the member of each of the Audit Committee, Nomination Committee and Remuneration Committee. Mr. E Wong joined the Group in February 2017. He has over 25 years of experience in venture capital, corporate finance, business development and general management. Mr. E Wong has served as the president and group chief financial officer of KVB Kunlun Holdings Limited (“KVB”) since November 2011 and as the chief financial officer and the company secretary of KVB’s group company, KVB Kunlun Financial Group Limited (the shares of which are listed on the Stock Exchange, HKEx stock code: 8077) since October 2014. Mr. E Wong has also served as an independent non-executive director of Renheng Enterprise Holdings Limited (HKEx stock code: 3628) since October 2011, HongDa Financial Holding Limited (HKEx stock code: 1822) since July 2014, Legend Strategy International Holdings Group Company Limited (HKEx stock code:1355) since November 2016 and Progressive Path Group Holdings Limited (HKEx stock code: 1581) since November 2016.
Mr. E Wong also served several positions at Adamas Finance Asia Limited (LSE stock code: ADAM), including its executive director from May 2008 to February 2014, its chief financial officer from May 2008 to October 2011 and its non-executive director since February 2014.
Mr. E Wong obtained a bachelor’s degree in business administration from The University of Hong Kong in 1991, a master’s degree of science in investment management from The Hong Kong University of Science and Technology in 1998 and a master’s degree of science in electronic engineering from The Chinese University of Hong Kong in 2008.
Mr. E Wong was admitted as a fellow member of the Association of Chartered Certified Accountants and the Hong Kong Institute of Certified Public Accountants in November 1999 and October 2002, respectively. He was admitted as a chartered financial analyst of the Institute of Chartered Financial Analysts in September 1998 and an associate member of the Institute of Chartered Accountants in England and Wales in January 2008. He is also acting as the president of the Hong Kong University Graduates Association, the deputy chairman of the HKU Convocation, the court member of The University of Hong Kong, a committee member of the Association of Chartered Certified Accountants Hong Kong and an executive director of the Hong Kong Society of Financial Analysts.
Listed Date 18 Jul 2001
Address 10th Floor, Everbright Centre, 108 Gloucester Road, Wanchai, Hong Kong
Telephone (852) 3966-8388
Facsimile (852) 2802-0026